HLA-DRB1 is associated with cefaclor-induced immediate hypersensitivity.
Cefaclor
Cephalosporin
Drug hypersensitivity
Immediate hypersensitivity
Whole exome sequencing
Journal
The World Allergy Organization journal
ISSN: 1939-4551
Titre abrégé: World Allergy Organ J
Pays: United States
ID NLM: 101481283
Informations de publication
Date de publication:
May 2024
May 2024
Historique:
received:
16
10
2023
revised:
13
03
2024
accepted:
22
03
2024
medline:
19
4
2024
pubmed:
19
4
2024
entrez:
19
4
2024
Statut:
epublish
Résumé
Drug-induced hypersensitivity such as anaphylaxis is an important cause of drug-related morbidity and mortality. Cefaclor is a leading cause of drug induced type I hypersensitivity in Korea, but little is yet known about genetic biomarkers to predict this hypersensitivity reaction. We aimed to evaluate the possible involvement of genes in cefaclor induced type I hypersensitivity. Whole exome sequencing (WES) and HLA genotyping were performed in 43 patients with cefaclor induced type I hypersensitivity. In addition, homology modeling was performed to identify the binding forms of cefaclor to HLA site. Anaphylaxis was the most common phenotype of cefaclor hypersensitivity (90.69%). WES results show that rs62242177 and rs62242178 located in LIMD1 region were genome-wide significant at the 5 × 10 LIMD1, HLA-DRB1∗04:03 and HLA-DRB1∗14:54 may affect susceptibility to cefaclor induced type I hypersensitivity. Further confirmative studies with a larger patient population should be performed to ascertain the role of HLA-DRB1 and LIMD1 in the development of cefaclor induced hypersensitivity.
Sections du résumé
Background
UNASSIGNED
Drug-induced hypersensitivity such as anaphylaxis is an important cause of drug-related morbidity and mortality. Cefaclor is a leading cause of drug induced type I hypersensitivity in Korea, but little is yet known about genetic biomarkers to predict this hypersensitivity reaction. We aimed to evaluate the possible involvement of genes in cefaclor induced type I hypersensitivity.
Methods
UNASSIGNED
Whole exome sequencing (WES) and HLA genotyping were performed in 43 patients with cefaclor induced type I hypersensitivity. In addition, homology modeling was performed to identify the binding forms of cefaclor to HLA site.
Results
UNASSIGNED
Anaphylaxis was the most common phenotype of cefaclor hypersensitivity (90.69%). WES results show that rs62242177 and rs62242178 located in LIMD1 region were genome-wide significant at the 5 × 10
Conclusion
UNASSIGNED
LIMD1, HLA-DRB1∗04:03 and HLA-DRB1∗14:54 may affect susceptibility to cefaclor induced type I hypersensitivity. Further confirmative studies with a larger patient population should be performed to ascertain the role of HLA-DRB1 and LIMD1 in the development of cefaclor induced hypersensitivity.
Identifiants
pubmed: 38638799
doi: 10.1016/j.waojou.2024.100901
pii: S1939-4551(24)00032-2
pmc: PMC11021981
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100901Informations de copyright
© 2024 The Authors.
Déclaration de conflit d'intérêts
The authors have no conflict of interest relevant to this article to disclose.
Références
Curr Opin Allergy Clin Immunol. 2004 Aug;4(4):261-6
pubmed: 15238790
Clin Exp Allergy. 2005 Sep;35(9):1234-42
pubmed: 16164453
Clin Exp Allergy. 2005 Mar;35(3):339-44
pubmed: 15784113
Immunol Allergy Clin North Am. 2004 Aug;24(3):463-76, vi-vii
pubmed: 15242721
Curr Opin Allergy Clin Immunol. 2007 Aug;7(4):317-23
pubmed: 17620823
J Allergy Clin Immunol Pract. 2019 Jan;7(1):219-227.e4
pubmed: 29800753
Blood. 2014 Aug 21;124(8):1266-76
pubmed: 24970932
Allergy. 2013 Jul;68(7):938-44
pubmed: 23751142
J Hum Genet. 2014 Jan;59(1):5-15
pubmed: 24196381
Allergy. 2022 Feb;77(2):404-415
pubmed: 34037262
Emerg Med Clin North Am. 2022 Feb;40(1):39-55
pubmed: 34782090
J Allergy Clin Immunol. 2015 Jan;135(1):253-9
pubmed: 25224099
Nat Genet. 2016 Oct;48(10):1284-1287
pubmed: 27571263
Lancet. 2000 Oct 28;356(9240):1505-11
pubmed: 11081549
J Allergy Clin Immunol. 2015 Aug;136(2):236-44
pubmed: 26254050
J Allergy Clin Immunol. 2021 May;147(5):1830-1837.e15
pubmed: 33058932
FEBS J. 2019 Mar;286(5):963-974
pubmed: 30600590
Allergy. 2018 Sep;73(9):1833-1841
pubmed: 29517808
Genome Biol. 2017 Jan 27;18(1):19
pubmed: 28129774
Ann Allergy Asthma Immunol. 2022 Mar;128(3):335-337
pubmed: 34864189
Nat Commun. 2017 Nov 28;8(1):1826
pubmed: 29184056
J R Stat Soc Series B Stat Methodol. 2015 Jan 1;77(1):59-83
pubmed: 25642138
Am J Hum Genet. 2004 Apr;74(4):765-9
pubmed: 14997420